JP2024500698A5 - - Google Patents
Info
- Publication number
- JP2024500698A5 JP2024500698A5 JP2023536167A JP2023536167A JP2024500698A5 JP 2024500698 A5 JP2024500698 A5 JP 2024500698A5 JP 2023536167 A JP2023536167 A JP 2023536167A JP 2023536167 A JP2023536167 A JP 2023536167A JP 2024500698 A5 JP2024500698 A5 JP 2024500698A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- heart failure
- subject
- composition
- nyha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020904675A AU2020904675A0 (en) | 2020-12-15 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2020904675 | 2020-12-15 | ||
| AU2021900059A AU2021900059A0 (en) | 2021-01-12 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2021900059 | 2021-01-12 | ||
| AU2021902941 | 2021-09-10 | ||
| AU2021902941A AU2021902941A0 (en) | 2021-09-10 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2021903365A AU2021903365A0 (en) | 2021-10-20 | Method of treating progressive heart failure in subjects with Class II heart failure | |
| AU2021903365 | 2021-10-20 | ||
| US202163289868P | 2021-12-15 | 2021-12-15 | |
| PCT/US2021/063645 WO2022132986A2 (en) | 2020-12-15 | 2021-12-15 | Method of treating progressive heart failure in subjects with class ii heart failure |
| US63/289,868 | 2021-12-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500698A JP2024500698A (ja) | 2024-01-10 |
| JP2024500698A5 true JP2024500698A5 (enExample) | 2024-12-25 |
Family
ID=79686821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536167A Pending JP2024500698A (ja) | 2020-12-15 | 2021-12-15 | クラスｉｉ心不全を有する対象における進行性心不全を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240041934A1 (enExample) |
| JP (1) | JP2024500698A (enExample) |
| KR (1) | KR20230119676A (enExample) |
| AU (1) | AU2021403025A1 (enExample) |
| CA (1) | CA3202153A1 (enExample) |
| WO (1) | WO2022132986A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4663241A3 (en) | 2010-10-08 | 2026-03-25 | Mesoblast International Sàrl | Enhanced msc preparations |
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| US9205112B2 (en) * | 2007-04-23 | 2015-12-08 | Creative Medical Health, Inc. | Combination treatment of cardiovascular disease |
| KR20240056789A (ko) * | 2014-12-23 | 2024-04-30 | 메조블라스트 인터내셔널 에스에이알엘 | 진행성 심부전증의 예방 |
| US20190224240A1 (en) * | 2016-01-11 | 2019-07-25 | Cardiocell, Llc | Cell therapy for the treatment of non-ischemic heart failure |
-
2021
- 2021-12-15 KR KR1020237023192A patent/KR20230119676A/ko active Pending
- 2021-12-15 US US18/257,515 patent/US20240041934A1/en active Pending
- 2021-12-15 AU AU2021403025A patent/AU2021403025A1/en active Pending
- 2021-12-15 WO PCT/US2021/063645 patent/WO2022132986A2/en not_active Ceased
- 2021-12-15 CA CA3202153A patent/CA3202153A1/en active Pending
- 2021-12-15 JP JP2023536167A patent/JP2024500698A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2288373B1 (en) | Relaxin for use in treating of dyspnea associated with acute heart failure | |
| Rupp et al. | Intracoronary bone marrow cell application for terminal heart failure in children | |
| JP2017061453A (ja) | 慢性心不全の治療方法 | |
| CN110494154A (zh) | 心肌病、陈旧性心肌梗塞及慢性心力衰竭的治疗剂 | |
| Yang et al. | Vasculoprotective properties of enhanced external counterpulsation for coronary artery disease: beyond the hemodynamics | |
| Blatt et al. | Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy | |
| Sietsema et al. | Autologous CD34+ cell therapy for ischemic tissue repair | |
| Yajima et al. | A prostacyclin agonist and an omental flap increased myocardial blood flow in a porcine chronic ischemia model | |
| JP2024538839A5 (enExample) | ||
| Wang et al. | Recombinant human hepatocyte growth factor transfection alleviates hyperkinetic pulmonary artery hypertension in rabbit models | |
| Chaudhry et al. | Myxedema heart disease: a rare disease entity: case report and brief review of the literature | |
| CN1222310C (zh) | 肝实质细胞增殖因子药用制剂 | |
| Mai et al. | Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines | |
| Baweja et al. | A case of incidental giant cell myocarditis presenting after COVID-19 mRNA vaccination | |
| Kong et al. | Effects of adrenomedullin on the cell numbers and apoptosis of endothelial progenitor cells | |
| Si et al. | Anti-HLA DQ Antibodies Are Associated with Chronic Lung Allograft Dysfunction in a Pediatric Lung Transplant Population | |
| Wang et al. | Severe Myocarditis Caused by XELOX Chemotherapy After Rectal Cancer Surgery: A Case Report | |
| Kaur et al. | Refractory Ventricular Tachycardia Storm: A case report and review of literature | |
| Damayanti et al. | Mesenchymal Stem Cells Role in COVID-19 Myocardial Injury | |
| Kondo et al. | Long-term prognosis of patients with mildly dilated cardiomyopathy | |
| Ito et al. | Efficacy of combined therapy with DOA, DOB, and HANP in severe congestive heart failure due to cardiac sarcoidosis | |
| Arima et al. | Clinical features of patients with eosinophilic myocarditis | |
| CN107050435B (zh) | 一种钠尿肽极化液及其制备方法和应用 | |
| Shinagawa et al. | First-pass Perfusion Defect of the Subendocardium by Cardiac Magnetic Resonance Indicates the Microvascular Myocardial Ischemia | |
| WO2025133111A1 (en) | Cgrp receptor agonists in ischemic heart disease |